Market Place
Sourcing Support
Agomab Secures $89 Million Series D For Fibrosis Pipeline
25 Oct 2024 //
BUSINESSWIRE
Agomab Appoints Pierre Kemula As Chief Financial Officer
11 Jul 2024 //
BUSINESSWIRE
Agomab Appoints David Epstein As Board Chairman
09 Jul 2024 //
BUSINESSWIRE
Agomab Gets Orphan Status For AGMB-447 In Pulmonary Fibrosis
06 Jun 2024 //
BUSINESSWIRE
Agomab Starts Phase 1 Clinical Study for AGMB-447 in Pulmonary Fibrosis
14 Dec 2023 //
BUSINESSWIRE
Agomab Appoints Angelika Jahreis as Member of the Board of Directors
29 Nov 2023 //
BUSINESSWIRE
Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
11 Oct 2023 //
BUSINESSWIRE
Agomab uses $100M series C to push Crohn`s drug through phase 2
11 Oct 2023 //
FIERCE BIOTECH
Agomab Receives FDA Fast Track Designation for AGMB-129
05 Oct 2023 //
BUSINESSWIRE
Agomab Reports Positive Phase 1 Results with AGMB-129
02 Feb 2023 //
BUSINESSWIRE
Agomab Raises Additional $40.5 Million Through Series B Extension
13 Jul 2022 //
BUSINESSWIRE
Agomab to Present at 40th Annual J.P. Morgan Healthcare Conference
12 Jan 2022 //
BUSINESSWIRE
Agomab Therapeutics Completes Acquisition of Origo Biopharma
14 Dec 2021 //
BUSINESSWIRE
Agomab Therapeutics to Acquire Origo Biopharma
28 Oct 2021 //
BUSINESSWIRE
AgomAb Therapeutics Expands Senior Team with General Counsel
01 Jul 2021 //
BUSINESSWIRE
AgomAb Raises $74 Million Series B to Advance Regenerative Pathway Modulators
09 Mar 2021 //
BUSINESSWIRE
AgomAb Raises $74 Million Series B to Advance Regenerative Pathway Modulators
09 Mar 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.